Younes Belkouchi

Mr. Younes Belkouchi

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2023 in Diagnostic and Interventional Imaging
Verified
Journal Article
Closed access
ADAissam Djahnine
Aissam Djahnine
CLCarole Lazarus
Carole Lazarus
MLMathieu Lederlin
Mathieu Lederlin
SMSébastien Mulé
Sébastien Mulé
RWRafael Wiemker
Rafael Wiemker
LBLoic Boussel
Loic Boussel

5 October 2022 in Diagnostic and Interventional Imaging
Verified
Journal Article
Closed access
SMSébastien Mulé
Sébastien Mulé
LLLittisha LAWRANCE
Littisha LAWRANCE
YBYounes Belkouchi
Younes Belkouchi
VVValérie Vilgrain
Valérie Vilgrain
MLMaité Lewin
Maité Lewin
NLNathalie Lassau
Nathalie Lassau

15 June 2023 in Diagnostic and Interventional Imaging
Verified
Journal Article
Closed access
YBYounes Belkouchi
Younes Belkouchi
MLMathieu Lederlin
Mathieu Lederlin
AAAmira Ben Afia
Amira Ben Afia
CFClement Fabre
Clement Fabre
GFGilbert Ferretti
Gilbert Ferretti
NLNathalie Lassau
Nathalie Lassau

5 January 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
PDPierre Decazes
Pierre Decazes
SASAMY AMMARI
SAMY AMMARI
APAntoine de Prévia
Antoine de Prévia
LMLéo Antoine MOTTAY
Léo Antoine MOTTAY
LLLittisha LAWRANCE
Littisha LAWRANCE
NLNathalie Lassau
Nathalie Lassau
Background: Body composition could help to better define the prognosis of cancers treated with anti-angiogenics. The aim of this study is to evaluate the prognostic value of 3D and 2D anthropometric parameters in patients given anti-angiogenic treatments. Methods: 526 patients with different types of cancers were retrospectively included. The software Anthropometer3DNet was used to measure automatically fat body mass (FBM3D), muscle body mass (MBM3D), visceral fat mass (VFM3D) and subcutaneous fat mass (SFM3D) in 3D computed tomography. For comparison, equivalent two-dimensional measurements at the L3 level were also measured. The area under the curve (AUC) of the receiver operator characteristics (ROC) was used to determine the parameters’ predictive power and optimal cut-offs. A univariate analysis was performed using Kaplan–Meier on the overall survival (OS). Results: In ROC analysis, all 3D parameters appeared statistically significant: VFM3D (AUC = 0.554, p = 0.02, cutoff = 0.72 kg/m2), SFM3D (AUC = 0.544, p = 0.047, cutoff = 3.05 kg/m2), FBM3D (AUC = 0.550, p = 0.03, cutoff = 4.32 kg/m2) and MBM3D (AUC = 0.565, p = 0.007, cutoff = 5.47 kg/m2), but only one 2D parameter (visceral fat area VFA2D AUC = 0.548, p = 0.034). In log-rank tests, low VFM3D (p = 0.014), low SFM3D (p < 0.0001), low FBM3D (p = 0.00019) and low VFA2D (p = 0.0063) were found as a significant risk factor. Conclusion: automatic and 3D body composition on pre-therapeutic CT is feasible and can improve prognostication in patients treated with anti-angiogenic drugs. Moreover, the 3D measurements appear to be more effective than their 2D counterparts.

25 October 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
YBYounes Belkouchi
Younes Belkouchi
LNLaetitia Nebot-Bral
Laetitia Nebot-Bral
LLLittisha Lawrance
Littisha Lawrance
MKMichele Kind
Michele Kind
CDClémence David
Clémence David
AHAntoine Hollebecque
Antoine Hollebecque
Background: Anti-PD-(L)1 treatment is indicated for patients with mismatch repair-deficient (MMRD) tumors, regardless of tumor origin. However, the response rate is highly heterogeneous across MMRD tumors. The objective of the study is to find a score that predicts anti-PD-(L)1 response in patients with MMRD tumors.Methods: Sixty-one patients with various origin of MMRD tumors and treated with anti-PD-(L)1 were retrospectively included in this study. An expert radiologist annotated all tumors present at the baseline and first evaluation CT-scans for all the patients by circumscribing them on their largest axial axis (single slice), allowing us to compute an approximation of their tumor volume. In total, 2120 lesions were annotated, which led to the computation of the total tumor volume for each patient. The RECIST sum of target lesions’ diameters and neutrophile-to-lymphocyte (NLR) were also reported at both examinations. These parameters were determined at baseline and first evaluation and the variation between the first evaluation and baseline was calculated, to determine a comprehensive score for overall survival (OS) and progression-free survival (PFS).Results: Total tumor volume at baseline was found to be significantly correlated to the OS (p-value: 0.005) and to the PFS (p-value:<0.001). The variation of the RECIST sum of target lesions’ diameters, total tumor volume and NLR were found to be significantly associated to the OS (p-values:<0.001, 0.006,<0.001 respectively) and to the PFS (<0.001,<0.001, 0.007 respectively). The concordance score combining total tumor volume and NLR variation was better at stratifying patients compared to the tumor volume or NLR taken individually according to the OS (pairwise log-rank test p-values: 0.033,<0.001, 0.002) and PFS (pairwise log-rank test p-values: 0.041,<0.001, 0.003).Conclusion: Total tumor volume appears to be a prognostic biomarker of anti-PD-(L)1 response to immunotherapy in metastatic patients with MMRD tumors. Combining tumor volume and NLR with a simple concordance score stratifies patients well according to their survival and offers a good predictive measure of response to immunotherapy.

4 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
RNRaphaël Naccache
Raphaël Naccache
YBYounes Belkouchi
Younes Belkouchi
LLLittisha LAWRANCE
Littisha LAWRANCE
BBBaya Benatsou
Baya Benatsou
JHJoya Hadchiti
Joya Hadchiti
NLNathalie Lassau
Nathalie Lassau
Purpose: The objective of our study is to propose fast, cost-effective, convenient, and effective biomarkers using the perfusion parameters from dynamic contrast-enhanced ultrasound (DCE-US) for the evaluation of immune checkpoint inhibitors (ICI) early response. Methods: The retrospective cohort used in this study included 63 patients with metastatic cancer eligible for immunotherapy. DCE-US was performed at baseline, day 8 (D8), and day 21 (D21) after treatment onset. A tumor perfusion curve was modeled on these three dates, and change in the seven perfusion parameters was measured between baseline, D8, and D21. These perfusion parameters were studied to show the impact of their variation on the overall survival (OS). Results: After the removal of missing or suboptimal DCE-US, the Baseline-D8, the Baseline-D21, and the D8-D21 groups included 37, 53, and 33 patients, respectively. A decrease of more than 45% in the area under the perfusion curve (AUC) between baseline and D21 was significantly associated with better OS (p = 0.0114). A decrease of any amount in the AUC between D8 and D21 was also significantly associated with better OS (p = 0.0370). Conclusion: AUC from DCE-US looks to be a promising new biomarker for fast, effective, and convenient immunotherapy response evaluation.